78 related articles for article (PubMed ID: 35253323)
1. Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma.
Kim Y; Jung KY; Kim YH; Xu P; Kang BE; Jo Y; Pandit N; Kwon J; Gariani K; Gariani J; Lee J; Verbeek J; Nam S; Bae SJ; Ha KT; Yi HS; Shong M; Kim KH; Kim D; Jung HJ; Lee CW; Kim KR; Schoonjans K; Auwerx J; Ryu D
Drug Resist Updat; 2024 Mar; 73():101054. PubMed ID: 38277756
[TBL] [Abstract][Full Text] [Related]
2. EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2.
Lai Y; Han X; Xie B; Xu Y; Yang Z; Wang D; Li W; Xie Y; Song W; Zhang X; Xia JQ; Zhang P
Cancer Sci; 2024 Apr; ():. PubMed ID: 38623968
[TBL] [Abstract][Full Text] [Related]
3. Contingent Synergistic Interactions between Non-Coding RNAs and DNA-Modifying Enzymes in Myelodysplastic Syndromes.
Symeonidis A; Chatzilygeroudi T; Chondrou V; Sgourou A
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555712
[TBL] [Abstract][Full Text] [Related]
4. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.
Yang Y; Li S; Wang Y; Zhao Y; Li Q
Signal Transduct Target Ther; 2022 Sep; 7(1):329. PubMed ID: 36115852
[TBL] [Abstract][Full Text] [Related]
5. Dicer-mediated miR-200b expression contributes to cell migratory/invasive abilities and cancer stem cells properties of breast cancer cells.
Hsu TW; Chen HA; Liao PH; Su YH; Chiu CF; Huang CY; Lin YJ; Hung CC; Yeh MH; Sung SY; Su CM
Aging (Albany NY); 2022 Aug; 14(16):6520-6536. PubMed ID: 35951366
[TBL] [Abstract][Full Text] [Related]
6. A concise review of the regulatory, diagnostic, and prognostic implications of HOXB-AS3 in tumors.
Wu H; Ye J; Zhang M; Luo H
J Cancer; 2024; 15(3):714-728. PubMed ID: 38213732
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional suppression of Dicer by HOXB-AS3/EZH2 complex dictates sorafenib resistance and cancer stemness.
Tseng CF; Chen LT; Wang HD; Liu YH; Shiah SG
Cancer Sci; 2022 May; 113(5):1601-1612. PubMed ID: 35253323
[TBL] [Abstract][Full Text] [Related]
9. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
Hu J; Zhang J; Sun F; Qi M; Su P; Liu H; Gao L; Jiao M; Wu Z; Xiang L; Han B
Anticancer Drugs; 2019 Aug; 30(7):e0746. PubMed ID: 31305292
[TBL] [Abstract][Full Text] [Related]
10. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
Cai L; Wang Z; Liu D
Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
[TBL] [Abstract][Full Text] [Related]
11. lncRNA HOXB-AS3 promotes hepatoma by inhibiting p53 expression.
Zhang XM; Chen H; Zhou B; Zhang QY; Liao Y; Wang JS; Wang ZH
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6784-6792. PubMed ID: 30402841
[TBL] [Abstract][Full Text] [Related]
12. Targeting EZH2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma.
Wang Z; Dai J; Yan J; Zhang Y; Yin Z
J Cell Mol Med; 2019 Jul; 23(7):4770-4778. PubMed ID: 31087496
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2.
Wang S; Zhu Y; He H; Liu J; Xu L; Zhang H; Liu H; Liu W; Liu Y; Pan D; Chen L; Wu Q; Xu J; Gu J
Cancer Sci; 2013 Jun; 104(6):750-9. PubMed ID: 23421437
[TBL] [Abstract][Full Text] [Related]
14. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.
Kusakabe Y; Chiba T; Oshima M; Koide S; Rizq O; Aoyama K; Ao J; Kaneko T; Kanzaki H; Kanayama K; Maeda T; Saito T; Nakagawa R; Kobayashi K; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Nakamoto S; Yasui S; Mikata R; Muroyama R; Kanda T; Maruyama H; Kato J; Mimura N; Ma A; Jin J; Zen Y; Otsuka M; Kaneda A; Iwama A; Kato N
Sci Rep; 2021 Nov; 11(1):21396. PubMed ID: 34725436
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
